A Phase 2 interventional study of Placebo and PF-06882961 in Diabetes Mellitus, Type 2, sponsored by Pfizer. Completed at 83 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-06-30.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Diabetes Mellitus, Type 2 by Pfizer — 2 open to participants now, 3 under way, 3 of them phase 3. Diabetes Mellitus, Type 2 · Pfizer.
Among the 80 studies in Diabetes Mellitus, Type 2 by Pfizer, this one is the 7th largest by enrollment of the 79 interventional ones that give a count, is one of 2 that started in 2019, is one of 18 in phase 2, and was the 69th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →2 of the 80 studies in Diabetes Mellitus, Type 2 by Pfizer are open now, in 11 countries. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Brazil, Canada and 8 more countries
Ages 18+
By country, each count listing its studies:
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 412 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 50 across the 79 interventional studies, 32 across the 1 observational. Of the 77 that completed or were terminated, 39 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
1 of the studies in Diabetes Mellitus, Type 2 by Pfizer that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
Add it to your calendar (.ics) → With an account.
Among the 80 studies in Diabetes Mellitus, Type 2 by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multicenter, randomized, double-blind, placebo controlled, parallel group study is being conducted to provide data on efficacy, safety, tolerability and pharmacokinetics (PK) of multiple dose levels of PF-06882961 in adults with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin and/or diet and exercise. In addition, the study is intended to enable selection of efficacious doses for future clinical development of PF-06882961.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: PF-06882961
Drug: PF-06882961
Participants will be titrated up to 2 weeks to reach desired dose level
Drug: PF-06882961
Participants will be titrated up to 4 weeks to reach desired dose level
Drug: PF-06882961
Participants will be titrated up to 6 weeks to reach desired dose level
Drug: PF-06882961
4 matching placebo tablets taken twice a day (BID)
Participants will be randomized to one of 5 active doses (2.5, 10, 40, 80, or 120 mg), taking 4 tablets twice daily for 16 weeks.
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 16
HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.
Time frame: Baseline, Week 16
Percentage of Participants Achieving Less Than (<) 7% Glycated Hemoglobin (HbA1c) Levels
HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.
Time frame: Baseline, Week 16
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 2
HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.
Time frame: Baseline, Week 2
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 4
HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.
Time frame: Baseline, Week 4
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 6
HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.
Time frame: Baseline, Week 6
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 8
HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.
Time frame: Baseline, Week 8
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12
HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.
Time frame: Baseline, Week 12
Change From Baseline in Fasting Plasma Glucose at Week 2
The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 milligram per deciliter (mg/dL) to 99 mg/dL.
Time frame: Baseline, Week 2
Change From Baseline in Fasting Plasma Glucose at Week 4
The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.
Time frame: Baseline, Week 4
Change From Baseline in Fasting Plasma Glucose at Week 6
The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.
Time frame: Baseline, Week 6
Change From Baseline in Fasting Plasma Glucose at Week 8
The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.
Time frame: Baseline, Week 8
Change From Baseline in Fasting Plasma Glucose at Week 12
The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.
Time frame: Baseline, Week 12
Change From Baseline in Fasting Plasma Glucose at Week 16
The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.
Time frame: Baseline, Week 16
Change From Baseline in Body Weight at Week 2
Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.
Time frame: Baseline, Week 2
Change From Baseline in Body Weight at Week 4
Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.
Time frame: Baseline, Week 4
Change From Baseline in Body Weight at Week 6
Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.
Time frame: Baseline, Week 6
Change From Baseline in Body Weight at Week 8
Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.
Time frame: Baseline, Week 8
Change From Baseline in Body Weight at Week 12
Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.
Time frame: Baseline, Week 12
Change From Baseline in Body Weight at Week 16
Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.
Time frame: Baseline, Week 16
Number of Participants With Treatment Emergent Adverse Events (Adverse Events [AEs] and Serious Adverse Events [SAEs])
An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent.
Time frame: Baseline up to Week 21
Number of Participants With Treatment Emergent Clinical Laboratory Abnormalities Without Regard to Baseline Abnormality
Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, erythrocytes, reticulocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time, PT/INR, reticulocytes); chemistry (indirect bilirubin, direct bilirubin, protein, albumin, blood urea nitrogen, creatinine, creatine kinase, urate, calcium, sodium, potassium, chloride, bicarbonate, urine urobilinogen); urinalysis (pH, urine glucose, urine ketones, urine protein, urine hemoglobin, nitrites, leukocyte esterase, urine erythrocytes, urine leukocytes, urine hyaline casts, urine bilirubin); lipid panel (low density lipoprotein cholesterol, high density lipoprotein cholesterol).
Time frame: Baseline Through Week 21
Number of Participants With Treatment Emergent Vital Signs Abnormalities
Vital signs abnormality criteria: 1) supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP greater than or equal to (\>=) 30 mmHg; 5) change from baseline (increase or decrease) in supine DBP \>= 20 mmHg.
Time frame: Baseline through Week 21
Number of Participants With Treatment Emergent ECG Abnormalities
ECG categorical abnormality criteria: 1. PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): a) greater than or equal to (\>=) 300 millisecond (msec), b) \>=25% increase when baseline is \> 200 msec or \>=50% increase when baseline is less than or equal to (\<=) 200 msec. 2. QRS interval (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): a) \>=140 msec, b) \>=50% increase from baseline. 3. QTcF interval (QT corrected using the Fridericia formula): a) \>450 msec and \<=480 msec, b) \>480 msec and \<=500 msec, c) \>500 msec, d) \>30 msec and \<=60 msec increase from baseline, e) \>60 msec increase from baseline.
Time frame: Baseline Through Week 21
| Milestone | Placebo | PF-06882961 2.5mg BID | PF-06882961 10mg BID | PF-06882961 40mg BID | PF-06882961 80mg BID | PF-06882961 120mg BID |
|---|---|---|---|---|---|---|
| Started | 66 | 68 | 68 | 71 | 67 | 71 |
| Completed | 57 | 54 | 63 | 57 | 47 | 38 |
| Not completed | 9 | 14 | 5 | 14 | 20 | 33 |
| Withdrew: Adverse event | 5 | 2 | 3 | 8 | 15 | 24 |
| Withdrew: Lost to follow-up | 1 | 3 | 0 | 3 | 3 | 1 |
| Withdrew: No longer meets eligibility criteria | 1 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Other | 1 | 2 | 0 | 2 | 1 | 0 |
| Withdrew: Protocol violation | 1 | 2 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 4 | 2 | 0 | 1 | 7 |
| Milestone | Placebo | PF-06882961 2.5mg BID | PF-06882961 10mg BID | PF-06882961 40mg BID | PF-06882961 80mg BID | PF-06882961 120mg BID |
|---|---|---|---|---|---|---|
| Started | 57 | 54 | 63 | 57 | 47 | 38 |
| Completed | 57 | 54 | 62 | 57 | 47 | 38 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 0 |
HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.
| Percent | Placebo | PF-06882961 2.5 BID | PF-06882961 10 mg BID | PF-06882961 40 mg BID | PF-06882961 80 mg BID | PF-06882961 120 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 16 | -0.02 (-0.22 to 0.19) | -0.49 (-0.70 to -0.28) | -0.91 (-1.11 to -0.72) | -1.03 (-1.23 to -0.83) | -0.96 (-1.18 to -0.74) | -1.18 (-1.41 to -0.95) |
HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.
| Percentage of Participants | Placebo | PF-06882961 2.5 BID | PF-06882961 10 mg BID | PF-06882961 40 mg BID | PF-06882961 80 mg BID | PF-06882961 120 mg BID |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Less Than (<) 7% Glycated Hemoglobin (HbA1c) Levels | 7.7 | 30.8 | 54.1 | 58.2 | 65.2 | 60.5 |
HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.
| Percent | Placebo | PF-06882961 2.5 BID | PF-06882961 10 mg BID | PF-06882961 40 mg BID | PF-06882961 80 mg BID | PF-06882961 120 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 2 | -0.09 (-0.17 to -0.01) | -0.18 (-0.26 to -0.09) | -0.31 (-0.39 to -0.23) | -0.29 (-0.37 to -0.21) | -0.33 (-0.41 to -0.24) | -0.35 (-0.43 to -0.28) |
HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.
| Percent | Placebo | PF-06882961 2.5 BID | PF-06882961 10 mg BID | PF-06882961 40 mg BID | PF-06882961 80 mg BID | PF-06882961 120 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 4 | -0.08 (-0.19 to 0.04) | -0.38 (-0.50 to -0.26) | -0.51 (-0.62 to -0.39) | -0.63 (-0.74 to -0.52) | -0.58 (-0.70 to -0.46) | -0.64 (-0.75 to -0.53) |
HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.
| Percent | Placebo | PF-06882961 2.5 BID | PF-06882961 10 mg BID | PF-06882961 40 mg BID | PF-06882961 80 mg BID | PF-06882961 120 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 6 | -0.07 (-0.21 to 0.07) | -0.47 (-0.61 to -0.34) | -0.71 (-0.84 to -0.57) | -0.84 (-0.97 to -0.71) | -0.79 (-0.93 to -0.65) | -0.84 (-0.98 to -0.71) |
HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.
| Percent | Placebo | PF-06882961 2.5 BID | PF-06882961 10 mg BID | PF-06882961 40 mg BID | PF-06882961 80 mg BID | PF-06882961 120 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 8 | -0.13 (-0.29 to 0.03) | -0.50 (-0.66 to -0.34) | -0.78 (-0.93 to -0.62) | -0.97 (-1.13 to -0.82) | -0.92 (-1.09 to -0.76) | -1.02 (-1.18 to -0.86) |
HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.
| Percent | Placebo | PF-06882961 2.5 BID | PF-06882961 10 mg BID | PF-06882961 40 mg BID | PF-06882961 80 mg BID | PF-06882961 120 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12 | -0.09 (-0.28 to 0.10) | -0.53 (-0.72 to -0.34) | -0.88 (-1.06 to -0.70) | -1.06 (-1.25 to -0.88) | -0.91 (-1.12 to -0.71) | -1.11 (-1.32 to -0.91) |
The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 milligram per deciliter (mg/dL) to 99 mg/dL.
| mg/dL | Placebo | PF-06882961 2.5 BID | PF-06882961 10 mg BID | PF-06882961 40 mg BID | PF-06882961 80 mg BID | PF-06882961 120 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose at Week 2 | -5.58 (-12.66 to 1.49) | -22.72 (-29.78 to -15.65) | -21.96 (-28.91 to -15.01) | -27.79 (-34.60 to -20.98) | -24.18 (-31.28 to -17.08) | -30.92 (-37.66 to -24.17) |
The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.
| mg/dL | Placebo | PF-06882961 2.5 BID | PF-06882961 10 mg BID | PF-06882961 40 mg BID | PF-06882961 80 mg BID | PF-06882961 120 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose at Week 4 | -5.98 (-13.62 to 1.66) | -17.77 (-25.46 to -10.09) | -24.66 (-31.98 to -17.35) | -33.42 (-40.83 to -26.00) | -33.34 (-41.25 to -25.44) | -34.06 (-41.52 to -26.60) |
The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.
| mg/dL | Placebo | PF-06882961 2.5 BID | PF-06882961 10 mg BID | PF-06882961 40 mg BID | PF-06882961 80 mg BID | PF-06882961 120 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose at Week 6 | -0.88 (-8.62 to 6.86) | -16.78 (-24.67 to -8.89) | -26.41 (-33.88 to -18.94) | -30.89 (-38.47 to -23.30) | -28.36 (-36.51 to -20.21) | -32.65 (-40.44 to -24.87) |
The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.
| mg/dL | Placebo | PF-06882961 2.5 BID | PF-06882961 10 mg BID | PF-06882961 40 mg BID | PF-06882961 80 mg BID | PF-06882961 120 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose at Week 8 | -9.10 (-16.80 to -1.41) | -12.73 (-20.53 to -4.93) | -26.23 (-33.57 to -18.89) | -29.74 (-37.26 to -22.23) | -33.22 (-41.36 to -25.09) | -34.31 (-42.46 to -26.16) |
The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.
| mg/dL | Placebo | PF-06882961 2.5 BID | PF-06882961 10 mg BID | PF-06882961 40 mg BID | PF-06882961 80 mg BID | PF-06882961 120 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose at Week 12 | 1.21 (-7.93 to 10.35) | -6.49 (-15.70 to 2.73) | -22.56 (-31.17 to -13.95) | -32.01 (-40.89 to -23.14) | -30.45 (-40.26 to -20.64) | -32.38 (-42.83 to -21.94) |
The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.
| mg/dL | Placebo | PF-06882961 2.5 BID | PF-06882961 10 mg BID | PF-06882961 40 mg BID | PF-06882961 80 mg BID | PF-06882961 120 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose at Week 16 | 1.31 (-7.58 to 10.20) | -12.81 (-21.71 to -3.91) | -24.53 (-32.88 to -16.18) | -30.47 (-39.06 to -21.87) | -25.71 (-35.15 to -16.26) | -31.93 (-41.73 to -22.13) |
Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.
| Kilogram | Placebo | PF-06882961 2.5 BID | PF-06882961 10 mg BID | PF-06882961 40 mg BID | PF-06882961 80 mg BID | PF-06882961 120 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in Body Weight at Week 2 | -0.15 (-0.47 to 0.17) | -0.09 (-0.41 to 0.23) | -0.12 (-0.44 to 0.19) | -0.23 (-0.54 to 0.08) | -0.57 (-0.89 to -0.24) | -0.54 (-0.85 to -0.24) |
Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.
| Kilogram | Placebo | PF-06882961 2.5 BID | PF-06882961 10 mg BID | PF-06882961 40 mg BID | PF-06882961 80 mg BID | PF-06882961 120 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in Body Weight at Week 4 | -0.25 (-0.64 to 0.15) | -0.33 (-0.72 to 0.07) | -0.08 (-0.46 to 0.30) | -0.77 (-1.15 to -0.39) | -1.05 (-1.45 to -0.64) | -1.33 (-1.71 to -0.95) |
Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.
| Kilogram | Placebo | PF-06882961 2.5 BID | PF-06882961 10 mg BID | PF-06882961 40 mg BID | PF-06882961 80 mg BID | PF-06882961 120 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in Body Weight at Week 6 | -0.09 (-0.57 to 0.40) | -0.19 (-0.68 to 0.31) | -0.32 (-0.78 to 0.15) | -0.83 (-1.31 to -0.36) | -1.69 (-2.20 to -1.19) | -2.34 (-2.83 to -1.85) |
Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.
| Kilogram | Placebo | PF-06882961 2.5 BID | PF-06882961 10 mg BID | PF-06882961 40 mg BID | PF-06882961 80 mg BID | PF-06882961 120 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in Body Weight at Week 8 | -0.36 (-0.89 to 0.16) | -0.05 (-0.59 to 0.49) | -0.27 (-0.78 to 0.23) | -1.09 (-1.60 to -0.57) | -1.97 (-2.52 to -1.42) | -3.31 (-3.85 to -2.77) |
Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.
| Kilogram | Placebo | PF-06882961 2.5 BID | PF-06882961 10 mg BID | PF-06882961 40 mg BID | PF-06882961 80 mg BID | PF-06882961 120 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in Body Weight at Week 12 | -0.24 (-0.85 to 0.38) | -0.09 (-0.72 to 0.53) | -0.00 (-0.59 to 0.58) | -1.05 (-1.65 to -0.44) | -2.52 (-3.17 to -1.87) | -3.81 (-4.46 to -3.16) |
Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.
| Kilogram | Placebo | PF-06882961 2.5 BID | PF-06882961 10 mg BID | PF-06882961 40 mg BID | PF-06882961 80 mg BID | PF-06882961 120 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in Body Weight at Week 16 | -0.43 (-1.12 to 0.25) | 0.02 (-0.68 to 0.72) | -0.06 (-0.71 to 0.60) | -1.16 (-1.84 to -0.49) | -2.48 (-3.20 to -1.75) | -4.60 (-5.34 to -3.86) |
An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent.
| Participants | Placebo | PF-06882961 2.5 BID | PF-06882961 10 mg BID | PF-06882961 40 mg BID | PF-06882961 80 mg BID | PF-06882961 120 mg BID |
|---|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent AEs | 32 | 32 | 31 | 42 | 43 | 44 |
| Number of Participants With Treatment Emergent SAEs | 1 | 1 | 2 | 6 | 2 | 1 |
Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, erythrocytes, reticulocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time, PT/INR, reticulocytes); chemistry (indirect bilirubin, direct bilirubin, protein, albumin, blood urea nitrogen, creatinine, creatine kinase, urate, calcium, sodium, potassium, chloride, bicarbonate, urine urobilinogen); urinalysis (pH, urine glucose, urine ketones, urine protein, urine hemoglobin, nitrites, leukocyte esterase, urine erythrocytes, urine leukocytes, urine hyaline casts, urine bilirubin); lipid panel (low density lipoprotein cholesterol, high density lipoprotein cholesterol).
| Participants | Placebo | PF-06882961 2.5 BID | PF-06882961 10 mg BID | PF-06882961 40 mg BID | PF-06882961 80 mg BID | PF-06882961 120 mg BID |
|---|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Clinical Laboratory Abnormalities Without Regard to Baseline Abnormality | 60 | 57 | 57 | 57 | 60 | 64 |
Vital signs abnormality criteria: 1) supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP greater than or equal to (\>=) 30 mmHg; 5) change from baseline (increase or decrease) in supine DBP \>= 20 mmHg.
| Participants | Placebo | PF-06882961 2.5 BID | PF-06882961 10 mg BID | PF-06882961 40 mg BID | PF-06882961 80 mg BID | PF-06882961 120 mg BID |
|---|---|---|---|---|---|---|
| Supine SBP <90 mmHg | 0 | 0 | 0 | 0 | 0 | 0 |
| Supine SBP increase >=30 mmHg | 3 | 4 | 3 | 3 | 0 | 5 |
| Supine SBP decrease >=30 mmHg | 4 | 4 | 3 | 5 | 5 | 0 |
| Supine DBP <50 mmHg | 1 | 0 | 0 | 1 | 0 | 1 |
| Supine DBP increase >=20 mmHg | 1 | 1 | 2 | 3 | 3 | 3 |
| Supine DBP decrease >=20 mmHg | 3 | 4 | 1 | 3 | 2 | 1 |
| Supine pulse rate <40 bpm | 0 | 0 | 0 | 0 | 0 | 0 |
| Supine pulse rate >120 bpm | 0 | 0 | 0 | 0 | 0 | 0 |
ECG categorical abnormality criteria: 1. PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): a) greater than or equal to (\>=) 300 millisecond (msec), b) \>=25% increase when baseline is \> 200 msec or \>=50% increase when baseline is less than or equal to (\<=) 200 msec. 2. QRS interval (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): a) \>=140 msec, b) \>=50% increase from baseline. 3. QTcF interval (QT corrected using the Fridericia formula): a) \>450 msec and \<=480 msec, b) \>480 msec and \<=500 msec, c) \>500 msec, d) \>30 msec and \<=60 msec increase from baseline, e) \>60 msec increase from baseline.
| Participants | Placebo | PF-06882961 2.5 BID | PF-06882961 10 mg BID | PF-06882961 40 mg BID | PF-06882961 80 mg BID | PF-06882961 120 mg BID |
|---|---|---|---|---|---|---|
| PR interval ≥300 msec | 0 | 0 | 0 | 0 | 0 | 1 |
| %Change in PR interval ≥25/50% | 3 | 0 | 0 | 0 | 1 | 0 |
| QRS interval ≥140 msec | 1 | 1 | 0 | 0 | 0 | 0 |
| %Change in QRS interval ≥50% | 1 | 1 | 0 | 0 | 0 | 0 |
| QTcF interval >450 and ≤480 msec | 2 | 3 | 2 | 1 | 3 | 4 |
| QTcF interval >480 and ≤500 msec | 0 | 0 | 0 | 0 | 0 | 1 |
| QTcF interval >500 msec | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in QTcF interval >30 and ≤60 msec | 2 | 3 | 2 | 6 | 3 | 6 |
| Change in QTcF interval >60 msec | 0 | 0 | 1 | 1 | 0 | 3 |
Collected over Baseline up to Week 21. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/66 (0%) | 1/66 (1.5%) | 15/66 (22.7%) |
| PF-06882961 2.5mg BID | 1/68 (1.5%) | 1/68 (1.5%) | 21/68 (30.9%) |
| PF-06882961 10mg BID | 0/68 (0%) | 2/68 (2.9%) | 17/68 (25%) |
| PF-06882961 40mg BID | 2/71 (2.8%) | 6/71 (8.5%) | 33/71 (46.5%) |
| PF-06882961 80mg BID | 0/67 (0%) | 2/67 (3%) | 40/67 (59.7%) |
| PF-06882961 120mg BID | 0/71 (0%) | 1/71 (1.4%) | 35/71 (49.3%) |
| Event | Placebo | PF-06882961 2.5mg BID | PF-06882961 10mg BID | PF-06882961 40mg BID | PF-06882961 80mg BID | PF-06882961 120mg BID |
|---|---|---|---|---|---|---|
| Ankle fractureInjury, poisoning and procedural complications | 1/66 | 0/68 | 0/68 | 0/71 | 0/67 | 0/71 |
| Cholecystitis acuteHepatobiliary disorders | 0/66 | 0/68 | 0/68 | 0/71 | 1/67 | 0/71 |
| HypertensionVascular disorders | 0/66 | 0/68 | 0/68 | 0/71 | 1/67 | 0/71 |
| AnaemiaBlood and lymphatic system disorders | 0/66 | 0/68 | 1/68 | 0/71 | 0/67 | 0/71 |
| Acute myocardial infarctionCardiac disorders | 0/66 | 1/68 | 0/68 | 0/71 | 0/67 | 0/71 |
| COVID-19 pneumoniaInfections and infestations | 0/66 | 1/68 | 0/68 | 1/71 | 0/67 | 0/71 |
| Multiple sclerosisNervous system disorders | 0/66 | 0/68 | 1/68 | 0/71 | 0/67 | 0/71 |
| PalpitationsCardiac disorders | 0/66 | 0/68 | 0/68 | 1/71 | 0/67 | 0/71 |
| Drug-induced liver injuryHepatobiliary disorders | 0/66 | 0/68 | 0/68 | 1/71 | 0/67 | 0/71 |
| PneumoniaInfections and infestations | 0/66 | 0/68 | 0/68 | 1/71 | 0/67 | 0/71 |
| Event | Placebo | PF-06882961 2.5mg BID | PF-06882961 10mg BID | PF-06882961 40mg BID | PF-06882961 80mg BID | PF-06882961 120mg BID |
|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 2/66 | 5/68 | 5/68 | 11/71 | 22/67 | 23/71 |
| VomitingGastrointestinal disorders | 0/66 | 0/68 | 1/68 | 5/71 | 11/67 | 18/71 |
| DiarrhoeaGastrointestinal disorders | 2/66 | 3/68 | 4/68 | 8/71 | 12/67 | 7/71 |
| DyspepsiaGastrointestinal disorders | 0/66 | 4/68 | 3/68 | 2/71 | 9/67 | 2/71 |
| HeadacheNervous system disorders | 4/66 | 4/68 | 1/68 | 5/71 | 2/67 | 7/71 |
| HyperglycaemiaMetabolism and nutrition disorders | 6/66 | 2/68 | 1/68 | 0/71 | 4/67 | 0/71 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/66 | 1/68 | 1/68 | 4/71 | 6/67 | 3/71 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/66 | 1/68 | 2/68 | 2/71 | 4/67 | 5/71 |
| Urinary tract infectionInfections and infestations | 0/66 | 1/68 | 0/68 | 5/71 | 3/67 | 1/71 |
| Decreased appetiteMetabolism and nutrition disorders | 0/66 | 2/68 | 0/68 | 2/71 | 1/67 | 5/71 |
A total of 412 participants were assigned to treatment, 411 of whom were treated; 1 participant randomized to the PF-06882961 120 mg BID group was not treated.
| Age, Continuous(Years) | Placebo | PF-06882961 2.5mg BID | PF-06882961 10mg BID | PF-06882961 40mg BID | PF-06882961 80mg BID | PF-06882961 120mg BID | Total |
|---|---|---|---|---|---|---|---|
| Mean (SD) | 57.9 ± 10.27 | 58.9 ± 9.30 | 58.1 ± 9.43 | 59.6 ± 8.58 | 58.4 ± 9.18 | 58.8 ± 9.43 | 58.6 ± 9.33 |
| Age, Customized(Participants) | Placebo | PF-06882961 2.5mg BID | PF-06882961 10mg BID | PF-06882961 40mg BID | PF-06882961 80mg BID | PF-06882961 120mg BID | Total |
|---|---|---|---|---|---|---|---|
| 18-44 Years | 6 | 4 | 7 | 2 | 5 | 8 | 32 |
| 45-64 Years | 44 | 43 | 41 | 45 | 42 | 44 | 259 |
| >=65 Years | 16 | 21 | 20 | 24 | 20 | 19 | 120 |
| Sex: Female, Male(Participants) | Placebo | PF-06882961 2.5mg BID | PF-06882961 10mg BID | PF-06882961 40mg BID | PF-06882961 80mg BID | PF-06882961 120mg BID | Total |
|---|---|---|---|---|---|---|---|
| Female | 33 | 30 | 33 | 37 | 32 | 37 | 202 |
| Male | 33 | 38 | 35 | 34 | 35 | 34 | 209 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | PF-06882961 2.5mg BID | PF-06882961 10mg BID | PF-06882961 40mg BID | PF-06882961 80mg BID | PF-06882961 120mg BID | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 24 | 22 | 17 | 24 | 23 | 18 | 128 |
| Not Hispanic or Latino | 42 | 46 | 50 | 47 | 44 | 52 | 281 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 0 | 1 | 2 |
| Race/Ethnicity, Customized(Participants) | Placebo | PF-06882961 2.5mg BID | PF-06882961 10mg BID | PF-06882961 40mg BID | PF-06882961 80mg BID | PF-06882961 120mg BID | Total |
|---|---|---|---|---|---|---|---|
| White | 57 | 57 | 53 | 58 | 59 | 59 | 343 |
| Black or African American | 2 | 4 | 10 | 6 | 1 | 4 | 27 |
| Asian | 5 | 7 | 4 | 6 | 6 | 7 | 35 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 0 | 1 | 2 |
| Not reported | 1 | 0 | 1 | 1 | 1 | 0 | 4 |
| Age Range(Years) | Placebo | PF-06882961 2.5mg BID | PF-06882961 10mg BID | PF-06882961 40mg BID | PF-06882961 80mg BID | PF-06882961 120mg BID | Total |
|---|---|---|---|---|---|---|---|
| Median | 59.0 (28 to 76) | 59.0 (38 to 74) | 60.0 (38 to 75) | 61.0 (31 to 75) | 58.0 (35 to 75) | 60.0 (40 to 74) | 59.0 (28 to 76) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Oct 2019 to primary completion in Jun 2021, 19 months.
Results were first posted in Jun 2022, 1 year after primary completion.
Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 19 months is above that.
Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Danuglipron